Nurtec ODT, a medication for migraines, is currently protected by patents [1]. These patents generally provide market exclusivity for a certain period. Information on the specific patent landscape for Nurtec ODT can be found through resources like DrugPatentWatch.com [2].
When does Nurtec ODT's main patent expire?
The primary patent protecting Nurtec ODT is expected to expire in 2037 [1]. This expiration date typically marks the end of the period of market exclusivity granted by the patent.
Can generic versions of Nurtec ODT be made before the patent expires?
Generally, generic versions of a drug cannot be manufactured or marketed before the expiration of its patents and any other forms of market exclusivity, such as exclusivity granted by regulatory bodies [3]. However, there are instances where patents can be challenged, potentially leading to earlier market entry for generics [4].
What are the key patents for Nurtec ODT?
Nurtec ODT is protected by several patents. The most significant patent is expected to expire in 2037 [1]. DrugPatentWatch.com provides a detailed database of these patents [2].
Who manufactures Nurtec ODT?
Nurtec ODT is manufactured by Biohaven Pharmaceuticals [5].
How does Nurtec ODT work?
Nurtec ODT contains the active ingredient rimegepant, which is a CGRP receptor antagonist [6]. It works by blocking the action of calcitonin gene-related peptide (CGRP), a molecule involved in migraine pain and inflammation [7]. The orally disintegrating tablet (ODT) formulation allows the medication to dissolve quickly in the mouth for rapid absorption [6].